Novo Nordisk A/S (NYSE: NVO) announced that the long‑term weight management indication of Wegovy (semaglutide) has been approved for update by China’s National Medical Products Administration (NMPA), further covering populations that meet China’s criteria for overweight and obesity in adults – a label expansion supported by the China‑specific STEP 12 Phase III trial showing approximately 17% average weight reduction in lower‑BMI Asian populations.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Indication update approved – long‑term weight management |
| Product | Wegovy (semaglutide) injection, once‑weekly |
| Updated Indication | Long‑term weight management in adult patients, as an adjunct to a reduced‑calorie diet and increased physical activity |
| BMI Criteria (China‑Specific) | ≥ 28 kg/m² (obesity); or ≥ 24 to < 28 kg/m² (overweight) with at least one weight‑related comorbidity |
| Qualifying Comorbidities | Hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease |
| Approval Date | 23 Oct 2026 |
| Supporting Evidence | STEP 12 Phase III trial (mainland China and Taiwan, China) |
Drug Profile & Mechanism of Action
- Molecule: Semaglutide – a glucagon‑like peptide‑1 receptor agonist (GLP‑1RA) delivered as a once‑weekly subcutaneous injection under the brand Wegovy.
- Class Leadership: Wegovy is the world’s first once‑weekly GLP‑1RA approved for long‑term weight management, establishing the category that has reshaped global obesity treatment.
- Mechanism: GLP‑1 receptor agonism reduces appetite and energy intake while improving glycemic control, addressing both weight and its metabolic comorbidities in a single weekly therapy.
- China Label Alignment: The updated indication aligns Wegovy’s label with China’s domestic BMI thresholds (obesity ≥ 28 kg/m²; overweight ≥ 24 kg/m²), which are lower than WHO international cutoffs – substantially widening the eligible patient pool versus the prior label.
Clinical Evidence – STEP 12 Phase III Trial
| Endpoint | Result (Wegovy) | Comparator | Relative Benefit |
|---|---|---|---|
| Primary Endpoint | Met | Placebo | Positive |
| Confirmatory Secondary Endpoints | All met | Placebo | Positive |
| Average Weight Reduction | ≈ 17% | Placebo | Clinically substantial |
| Patients with > 20% Weight Reduction | ≈ one‑third | – | Deep‑responder subgroup |
| Major Adverse Cardiovascular Events (MACE) | Risk reduced by up to 20% | Placebo | Cardiovascular protection signal |
The STEP 12 study was a randomized, double‑blind, placebo‑controlled, 44‑week Phase III trial conducted specifically in populations with overweight or obesity at lower BMI in mainland China and Taiwan, China – enrolling patients with 24 ≤ BMI < 28 kg/m² with at least one comorbidity, or 28 ≤ BMI < 30 kg/m². The trial met its primary endpoint and all confirmatory secondary endpoints, generating the China‑specific evidence base underpinning the NMPA indication update.
Market Impact & Outlook
- Addressable Population Expansion: By adopting China’s lower BMI cutoffs, the updated label opens Wegovy to the very large Chinese overweight population (BMI 24–28 kg/m²) with comorbidities – a group previously outside the approved indication and one of the world’s biggest weight‑management markets.
- Ethnicity‑Specific Evidence: STEP 12’s ~17% average weight loss in Asian lower‑BMI cohorts demonstrates that semaglutide’s efficacy extends to populations underrepresented in global obesity trials – a differentiator in China’s regulatory and payer environment.
- Cardiovascular Value Proposition: The up‑to‑20% MACE risk reduction strengthens Wegovy’s positioning beyond cosmetic weight loss toward cardiometabolic risk management, supporting formulary and reimbursement arguments.
- Competitive Landscape: The expanded label intensifies the GLP‑1 race in China, where domestic innovators are advancing their own weekly incretin therapies; first‑mover scale and a China‑specific Phase III dataset reinforce Novo Nordisk’s lead.
- Next Milestones: Commercial rollout to the newly eligible population; reimbursement access developments. Timing not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercialization, market uptake, reimbursement outcomes, and continued clinical performance of Wegovy (semaglutide) in China. Actual results may differ materially due to risks including pricing and reimbursement policy, competitive entry of generic and novel incretin therapies, supply constraints, and evolving clinical guidelines.-Fineline Info & Tech
